The Fact About ABBV-744 in combination with immunotherapy That No One Is Suggesting
In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or maybe the participants are not able to tolerate the study drugs.- "Our study disclosed the very important role of the KLF16/MYC regulatory axis in mod